Coherus Biosciences | CHRS - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.22B 329M 2026-03
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 73.25M 27.04M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
Baxter International USD 1.81B 587M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Fujifilm JPY 550.58B 40.74B 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Merck USD 2.94B 380M 2026-03
Myriad Genetics USD 63M 1.1M 2025-12
Pacira USD 50.74M 3.89M 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Teva Pharmaceutical Industries USD 2.01B 46M 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03
Xencor USD 61.66M 50.95M 2025-06
Zoetis USD 672M 71M 2026-03